Oncology - European Medical Journal

This site is intended for healthcare professionals

Continue

Oncology

Filter
EMJ
4 May 2016

Celyad announces oral presentation on NKR-2 T Cells Manufacturing for a First-in-Human Clinical Trial in AML and Multiple Myeloma

Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell…
EMJ
29 Apr 2016

Glycotope Appoints Dr. Alfredo Zurlo as Chief Medical Officer

Berlin, Germany, April 29, 2016 – Glycotope GmbH, a clinical-stage immuno-oncology company built on world-leading glyco-biology expertise, today…
EMJ
21 Apr 2016

MammaPrint Genetic Test Can Reduce Use of Post-Surgery Chemotherapy among Early-Stage Breast Cancer Patients

NEW ORLEANS — Among patients with early-stage breast cancer who were considered at high risk for disease recurrence based on clinical and biological…
EMJ
15 Apr 2016

Celyad Will Present Its NKR-2 Immuno-Oncology Clinical Program at 2016 ASCO Annual Meeting

Mont-Saint-Guibert, Belgium: Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell…
EMJ
15 Apr 2016

Patients with EGFR Expressing Non-Small-Cell Lung Cancer Benefit Most from Necitumumab Added to Chemotherapy

GENEVA, Switzerland, 15 April 2016: Patients with epidermal growth factor receptor (EGFR) expressing advanced squamous non-small-cell lung cancer benefit…
EMJ
15 Apr 2016

Immunotherapy with Live Bacterium Improves Response Rate in Malignant Pleural Mesothelioma

GENEVA, Switzerland, 14 April 2016: Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90% disease control and…
EMJ
12 Apr 2016

Heine H. Hansen Award Goes to Suresh Senan

Geneva, Switzerland, 11 April: The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC)…
EMJ
18 Mar 2016

STELARA® Induced Clinical Response and Remission in Phase 3 Study for the Treatment of Patients with Moderate to Severe Crohn’s Disease Who Had Previously Failed or Were Intolerant to Anti-TNF-Alpha Therapy

STELARA® Induced Clinical Response and Remission in Phase 3 Study for the Treatment of Patients with Moderate to Severe Crohn’s Disease Who Had Previously Failed or Were Intolerant to Anti-TNF-Alpha Therapy
We’ve noticed you’re accessing
from North/South America.